变化的血乙基胆酶活性在链毒素诱导的糖尿病高血压大鼠中并不反映肝功能受损
T Hodbod1, K Szmicsekova, A Cinakova
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Slovak Republic. anna.paul.hrabovska@uniba.sk.
Physiological research
|July 23, 2025
概括
血甲基胆酶 (BChE) 活性在患有并发性高血压和糖尿病的老鼠中增加. 这一发现表明,在这些条件下,血BChE可能不能可靠地表明肝损伤.
科学领域:
- 生物化学 生物化学
- 代谢障碍 代谢障碍 代谢障碍
- 心血管研究研究心血管研究
背景情况:
- 乙基胆酶 (BChE) 与代谢失衡有关,与血活性和脂质/葡萄糖代谢有关.
- 伴随性高血压和1型糖尿病 (DM) 存在复杂的代谢挑战.
研究的目的:
- 在伴随性高血压和1型糖尿病 (DM) 的大鼠模型中研究血BChE活性.
- 评估血BChE活性作为这种并发性疾病中肝损伤标志物的可靠性.
主要方法:
- 在雄性自发高血压大鼠 (SHR) 中使用链毒素 (STZ) 诱导1型糖尿病.
- 测量血BChE活性,脂质样本,肝酶 (ALT,AST),专蛋白和BChE mRNA的表达.
- 在Wistar控制,SHR和SHR+DM组之间进行比较.
主要成果:
- SHR+DM老鼠表现出高血压,高血糖,高三糖醇,胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,高密度胆固醇,低氨酸.
- 血BChE活性在Wistar和SHR大鼠中类似,但在SHR+DM中增加了43%.
- 肝脏BChE活性和mRNA表达在SHR和SHR+DM大鼠中显著下降.
结论:
- 在并发性高血压和糖尿病的小鼠模型中,血BChE活性升高.
- 肝脏BChE活动和表达在高血压和糖尿病大鼠中减少.
- 血BChE活性可能不是肝损伤的可靠临床标志物,患者有并发性高血压和糖尿病.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
01:28Diabetic Nephropathy
49
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
49